0 Ratings

ID

22717

Description

Study part: Adverse Events Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Keywords

  1. 6/11/17 6/11/17 -
Copyright Holder

GlaxoSmithKline

Uploaded on

June 11, 2017

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :


    No comments

    In order to download data models you must be logged in. Please log in or register for free.

    Adverse Events Screening Visit Mepolizumab HES NCT00086658

    Adverse Events Screening Visit

    ADVERSE EVENTS
    Description

    ADVERSE EVENTS

    Alias
    UMLS CUI-1
    C0877248 (Adverse event)
    LOINC
    MTHU014542
    AE's and SAE's related to study participation during the screening and Prednisone stabilization period reported?
    Description

    Adverse Events

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0877248 (Adverse event)
    LOINC
    MTHU014542

    Similar models

    Adverse Events Screening Visit

    Name
    Type
    Description | Question | Decode (Coded Value)
    Data type
    Alias
    Item Group
    ADVERSE EVENTS
    C0877248 (UMLS CUI-1)
    Adverse Events
    Item
    AE's and SAE's related to study participation during the screening and Prednisone stabilization period reported?
    boolean
    C0877248 (UMLS CUI [1])

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial